Measurement of Patient Views on the Attributes of Cancer Genomic Medicine in Japan (Patient View Study)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cancer Genomic Profiling
- Sponsor
- Bayer
- Enrollment
- 605
- Locations
- 1
- Primary Endpoint
- Best-Worst Scaling scores showing patient preferences for the attributes of the process of taking panel tests
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
Researchers are looking for a better way to treat people with solid tumors. One new way is called cancer genomic medicine. In cancer genomic medicine, doctors use tests to look at the genetic information in a solid tumor. These tests are called panel tests. The results of the panel tests help doctors to choose the best type of medicine to treat that tumor.
In this study, the researchers want to learn more about what a large number of patients with solid tumors think are the burden and benefits of taking panel tests. The researchers also want to know what doctors who treat patients with solid tumors think about panel tests.
The study will include about 650 men and women in Japan who are at least 20 years old. About 340 of the participants will be patients with solid tumors who are taking medicine to help treat their tumors. About 310 of the patients will be doctors who are treating patients with solid tumors.
There will be 3 parts in this study. Part 1 will include patients with solid tumors. Parts 2 and 3 will include patients with solid tumors and doctors who are treating patients with solid tumors. In each part, the patients and doctors will answer questions about what they think of panel tests. During Part 1, all of the patients will answer questions in a teleconference. Some of the patients and physicians in Part 2 will also answer questions in a teleconference. During Part 2 and Part 3, all of the patients and doctors will complete an online questionnaire.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult female or male patient
- •Diagnosis of a solid tumor
- •Patients familiar with panel tests to be defined as:
- •Patients who have taken a panel test
- •Patients who have not taken a panel test
- •Patients who have tried or considered taking a panel test
- •Patients who have been offered a panel test but refused
- •Signed informed consent
- •Is 20 years of age or older
- •Part 2 and Part 3 (patients):
Exclusion Criteria
- •Non-Japanese speakers
- •Declaring to be too unwell to perform an interview
- •Part2 and Part 3 (patients):
- •Non-Japanese speakers
- •Declaring to be too unwell to complete the survey
- •Participation in the pilot study
- •Part 2 and Part 3 (physician):
- •Non-Japanese speakers
Outcomes
Primary Outcomes
Best-Worst Scaling scores showing patient preferences for the attributes of the process of taking panel tests
Time Frame: Up to 25 minutes
Respondents will choose "Best" or "Worst" for prepared questions.
Secondary Outcomes
- Ranking of Best-Worst scaling scores for patients and for doctors(Up to 25 minutes)
- Best-Worst Scaling scores showing doctor preferences for the attributes of the process of taking panel tests(Up to 25 minutes)
- Patient and doctor willingness to try/offer panel tests based on different hypothetical conditions of panel tests and drugs in cancer genomic medicine(Up to 25 minutes)